Chenyu Lin, MD

Articles by Chenyu Lin, MD

Omidubicel Increases Availability of Allogeneic Stem Cell Transplant

September 23rd 2022

Chenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.

Long-Term Follow Up Shows Potential of Omidubicel in Hematologic Malignancies

ByChenyu Lin, MD

August 17th 2022

Chenyu Lin, MD, discusses the results of a 10-year follow up of patients who underwent allogenic stem cell therapy with the novel cell therapy omidubicel.

Chenyu Lin, MD

Articles by Chenyu Lin, MD

Omidubicel Increases Availability of Allogeneic Stem Cell Transplant

Long-Term Follow Up Shows Potential of Omidubicel in Hematologic Malignancies

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma